IMS Health Acquires Mercurial, extending Business Intelligence capability for the Australian market

SYDNEY, June 2nd, 2015 – IMS Health has acquired Mercurial, a leading Cloud Business Intelligence provider of information, technology and services in the Australian and New Zealand markets.


Tor Constantino
Media Relations

Founded in 2006, Mercurial provides services specialising in sales and marketing effectiveness, performance management and cloud-based business intelligence to a wide range of healthcare companies, including pharmaceutical and consumer health organisations.

“Mercurial’s live and secure cloud-based business intelligence platform – MiPortal – has been the clear market leader providing healthcare companies with the ability to rapidly deploy enterprise wide BI solutions,” said Andrew Sutton, General Manager of IMS Health Australia,  “Combining Mercurial’s MiPortal with IMS Health’s suite of market leading information assets will enable simpler integration of the best information and the best technology solutions for our clients.”

Details of the agreement have not been publicly disclosed.

About IMS Health

IMS Health (NYSE:IMS) is a leading global information and technology services company providing clients in the healthcare industry with comprehensive solutions to measure and improve their performance. End-to-end proprietary applications and configurable solutions connect 10+ petabytes of complex healthcare data through the IMS One™ cloud platform, providing comprehensive insights into diseases, treatments, costs and outcomes. The company’s 15,000 employees blend global consistency and local market knowledge across 100 countries to help clients run their operations more efficiently. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.

As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes. Additional information is available at